Arcellx provides third quarter 2023 financial results and business highlights

-- recently released ash abstract for the company's phase 1 cart-ddbcma trial demonstrated that median duration of response, progression free survival, and overall survival not reached with median follow-up of 22 months after cart-ddbcma infusion -- -- company to present new patient data from its phase 1 cart-ddbcma trial during an oral presentation with a median follow-up of 26.5 months at the 65th ash annual meeting in december -- redwood city, calif., nov. 13, 2023 /prnewswire/ -- arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended september 30, 2023 and provided recent business highlights.
ACLX Ratings Summary
ACLX Quant Ranking